THURSDAY, May 6, 2021 -- A four-month rifapentine-based regimen containing moxifloxacin is noninferior to a standard six-month regimen for treatment of tuberculosis, according to a study published in the May 6 issue of the New England Journal of Medicine.
Susan E. Dorman, M.D., from the Medical University of South Carolina in Charleston, and colleagues conducted an open-label, phase 3 trial involving persons with newly diagnosed pulmonary tuberculosis from 13 countries to compare two four-month rifapentine-based regimens to a standard six-month regimen consisting of rifampin, isoniazid, pyrazinamide, and ethambutol (control). In one four-month regimen, rifampin was replaced with rifapentine, while in the other, rifampin and ethambutol were replaced with rifapentine and moxifloxacin, respectively.
A total of 2,234 participants could be assessed for the primary outcome of survival free of tuberculosis at 12 months: 726 in the control group, 756 in the rifapentine-moxifloxacin group, and 752 in the rifapentine group. The researchers found that in the microbiologically eligible population and in the assessable population, rifapentine with moxifloxacin was noninferior to control with respect to the percentage of participants who had an unfavorable outcome (15.5 versus 14.6 percent and 11.6 versus 9.6 percent, respectively). In the secondary and sensitivity analyses, noninferiority was shown. Rifapentine without moxifloxacin was not noninferior to control in either population.
"Noninferiority of the rifapentine-moxifloxacin regimen to the control regimen was confirmed across analysis populations as well as in sensitivity and prespecified subgroup analyses," the authors write.
Two authors disclosed financial ties to the pharmaceutical industry.
1127-74-8,1,2,3,4-Tetrahydro-benzo[b]azepin-5-one
Read More4038-14-6,(3,4-dimethoxyphenyl)-phenylmethanone
Read More2338-76-3,2-[3-(trifluoromethyl)phenyl]acetonitrile
Read More351-35-9,2-[3-(trifluoromethyl)phenyl]acetic acid
Read More2997-92-4,2,2'-Azobis(2-methylpropionamidine) dihydrochloride
Read More95585-78-7,L-Phenylalanine, 1-methylethyl ester, hydrochloride
Read More20324-87-2,Disodium 7,7'-(carbonyldiimino)bis(4-hydroxynaphthalene-2-sulphonate)
Read More182498-32-4,1-(2-bromophenyl)-3-(2-hydroxy-4-nitrophenyl)urea
Read More1101854-58-3,(4-nitrophenyl) 4-[bis(1,3-benzodioxol-5-yl)-hydroxymethyl]piperidine-1-carboxylate
Read More170565-89-6,N,N-dimethyl-2-oxo-1,3-dihydroindole-5-sulfonamide
Read More1460-59-9,5,6,11,12-tetrahydrodibenzo[1,2-b:1',2'-g][8]annulene
Read More284035-33-2,2-chloro-6-[(2R)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]benzonitrile
Read More440662-09-9,N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methyl-1-oxo-1,2-dihydroisoquinoline-4-carboxamide
Read More932986-18-0,N-[2-[2-(4-chlorophenyl)-1,3-thiazol-4-yl]ethyl]butanamide
Read More1234015-52-1,5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile
Read More1651890-44-6,3'-Methyl-3''-[(1E)-2-phenylethenyl]-3,2':5',2'':5'',3'''-quaterpyridine
Read More1469924-27-3,3-[4'-(Dimethylamino)-3-biphenylyl]-1,1-dimethylure
Read More3897-94-7,8-Methoxy-N,N-dipropyl-1,2,3,4-tetrahydro-2-naphthalenamine
Read More1202759-32-7,4-{4-[(4-{[3-(Acryloylamino)phenyl]amino}-5-fluoro-2-pyrimidinyl) amino]phenoxy}-N-methyl-2-pyridinecarboxamide
Read More71145-03-4,1,4-Dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)-pyridine-5-carboxylic acid methyl ester
Read More500579-04-4,2-[[3-[[2-(dimethylamino)phenyl]methyl]-2-pyridin-4-yl-1,3-diazinan-1-yl]methyl]-N,N-dimethylaniline
Read More1443437-74-8,N-(4-chlorophenyl)-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide
Read More1125-29-7 1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid
Read More23362-56-3 [2-(aminocarbonyl)phenyl]acetic acid
Read More103788-65-4 2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethan-1-ol
Read More120503-69-7 2-Amino-6-cyclopropylamino-9H-purine
Read More